Frank Ruffo Email Address

Chief Financial Officer and Co-Founder

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in dermatology. Our lead drug candidate A-101 is being developed as an in-office treatment for seborrheic keratosis (SK), a common non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts. In September 2015, Aclaris acquired a portfolio of oral and topical Janus Kinase (JAK) inhibitor compounds for the treatment of alopecia areata and other dermatological conditions. Aclaris is led by a management team with rich experience and expertise in dermatology and dermatological drug development.

Senior Financial Executive with 35 years of biotech and specialty pharmaceutical management expertise in early stage through fully commercial operations. Extensive experience in financial and operations management including financial and SEC reporting and operational and financial planning & analysis. Strategic and commercial experience includes VC funding, IPOs and other public & private offerings; banking, M&A, product and technology licensing, investor relations, treasury, tax planning, risk management, internal control implementation and SOX compliance, customer operations, pharmaceutical logistics & distribution, manufacturing development and facilities planning.